LAVA Therapeutics (LVTX) Competitors $1.58 -0.04 (-2.47%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$1.59 +0.01 (+0.63%) As of 04:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LVTX vs. SAVA, IVVD, ACTU, PYXS, ELDN, PEPG, ANRO, CTOR, THTX, and CGENShould you be buying LAVA Therapeutics stock or one of its competitors? The main competitors of LAVA Therapeutics include Cassava Sciences (SAVA), Invivyd (IVVD), Actuate Therapeutics (ACTU), Pyxis Oncology (PYXS), Eledon Pharmaceuticals (ELDN), PepGen (PEPG), Alto Neuroscience (ANRO), Citius Oncology (CTOR), Theratechnologies (THTX), and Compugen (CGEN). These companies are all part of the "pharmaceutical products" industry. LAVA Therapeutics vs. Its Competitors Cassava Sciences Invivyd Actuate Therapeutics Pyxis Oncology Eledon Pharmaceuticals PepGen Alto Neuroscience Citius Oncology Theratechnologies Compugen Cassava Sciences (NASDAQ:SAVA) and LAVA Therapeutics (NASDAQ:LVTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment. Does the media refer more to SAVA or LVTX? In the previous week, Cassava Sciences had 6 more articles in the media than LAVA Therapeutics. MarketBeat recorded 6 mentions for Cassava Sciences and 0 mentions for LAVA Therapeutics. Cassava Sciences' average media sentiment score of 0.96 beat LAVA Therapeutics' score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the media. Company Overall Sentiment Cassava Sciences Positive LAVA Therapeutics Neutral Do insiders and institutionals hold more shares of SAVA or LVTX? 38.1% of Cassava Sciences shares are held by institutional investors. 2.4% of Cassava Sciences shares are held by company insiders. Comparatively, 9.5% of LAVA Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, SAVA or LVTX? Cassava Sciences has a beta of -0.98, indicating that its stock price is 198% less volatile than the S&P 500. Comparatively, LAVA Therapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500. Is SAVA or LVTX more profitable? Cassava Sciences' return on equity of -66.16% beat LAVA Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cassava SciencesN/A -66.16% -53.11% LAVA Therapeutics N/A -106.29%-38.24% Do analysts prefer SAVA or LVTX? Cassava Sciences presently has a consensus price target of $2.00, suggesting a potential downside of 49.75%. LAVA Therapeutics has a consensus price target of $2.69, suggesting a potential upside of 69.94%. Given LAVA Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe LAVA Therapeutics is more favorable than Cassava Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50LAVA Therapeutics 1 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.86 Which has better earnings and valuation, SAVA or LVTX? Cassava Sciences has higher earnings, but lower revenue than LAVA Therapeutics. Cassava Sciences is trading at a lower price-to-earnings ratio than LAVA Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCassava SciencesN/AN/A-$24.34M-$2.55-1.56LAVA Therapeutics$11.98M3.47-$25.11M-$1.05-1.50 SummaryLAVA Therapeutics beats Cassava Sciences on 8 of the 13 factors compared between the two stocks. Get LAVA Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LVTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LVTX vs. The Competition Export to ExcelMetricLAVA TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.62M$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-1.5021.5785.3527.60Price / Sales3.47271.49539.78202.41Price / CashN/A47.1237.9261.55Price / Book1.4910.1413.016.76Net Income-$25.11M-$52.31M$3.30B$275.88M7 Day Performance1.94%5.14%4.34%2.81%1 Month Performance0.64%14.68%9.49%9.24%1 Year Performance-1.25%30.98%84.83%35.42% LAVA Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LVTXLAVA Therapeutics1.5038 of 5 stars$1.58-2.5%$2.69+69.9%-3.7%$42.62M$11.98M-1.5060Analyst ForecastSAVACassava Sciences2.9516 of 5 stars$3.44-3.8%$2.00-41.8%-84.7%$166.42MN/A-1.3530Analyst ForecastIVVDInvivyd3.5595 of 5 stars$1.40-1.8%$5.14+268.3%+80.9%$166.39M$25.38M-1.51100Analyst ForecastACTUActuate Therapeutics1.7772 of 5 stars$7.08+0.8%$20.33+187.4%+0.9%$164.40MN/A0.0010Analyst ForecastPYXSPyxis Oncology1.9521 of 5 stars$2.62+5.9%$7.75+196.3%-12.1%$163.30M$16.15M-1.6560Analyst ForecastGap UpELDNEledon Pharmaceuticals2.3171 of 5 stars$2.73-4.7%$10.00+267.0%+9.5%$163.17MN/A-2.3310Positive NewsAnalyst ForecastGap UpPEPGPepGen3.7596 of 5 stars$4.82-2.8%$8.40+74.2%-50.1%$162.52MN/A-1.6730Analyst ForecastANROAlto Neuroscience2.197 of 5 stars$5.85-10.6%$9.80+67.5%-44.7%$158.40MN/A-2.45N/AAnalyst ForecastGap UpCTORCitius Oncology3.1288 of 5 stars$1.90+1.3%$6.00+216.6%+78.6%$158.08MN/A0.00N/ANews CoverageAnalyst ForecastGap DownTHTXTheratechnologiesN/A$3.42+0.9%N/A+182.6%$157.21M$84.38M-17.99140High Trading VolumeCGENCompugen1.5732 of 5 stars$1.73-3.6%$4.00+131.7%+4.6%$156.17M$27.86M-7.9570News CoverageAnalyst ForecastGap Up Related Companies and Tools Related Companies Cassava Sciences Alternatives Invivyd Alternatives Actuate Therapeutics Alternatives Pyxis Oncology Alternatives Eledon Pharmaceuticals Alternatives PepGen Alternatives Alto Neuroscience Alternatives Citius Oncology Alternatives Theratechnologies Alternatives Compugen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LVTX) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share LAVA Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
